Skip to content

Advancing Focal Liver Lesions Diagnosis: Harnessing the power of Deep Learning with Large-Scale Data and Multi-Stage CT Imaging

Advancing Focal Liver Lesions Diagnosis: Harnessing the power of Deep Learning with Large-Scale Data and Multi-Stage CT Imaging

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400081913
Enrollment
Unknown
Registered
2024-03-14
Start date
2020-06-01
Completion date
Unknown
Last updated
2024-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), metastasis tumors (MET), focal nodular hyperplasia (FNH), hemangioma (HEM), and cysts for personalized diagnosis.

Interventions

Gold Standard:1. HCC, ICC and Met were histopathologicaly or biopsy confirmed
2. The Cyst, FNH, and Hem were confirmed by 2 or more imaging modalities.
Index test:LiLNet classification and diagnosis system based on Resnet50

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
21 Years to 88 Years

Inclusion criteria

Inclusion criteria: 1. Patients were eighteen years older; 2. Patients did not have a history of hepatectomy, transarterial chemotherapy (TACE), or radiofrequency ablation (RFA) before the CT examination; 3. Nodules were pathologically confirmed or at least aunder a six months follow-up using two imaging modalities.

Exclusion criteria

Exclusion criteria: 1. Patients lacking complete CT images; 2. Low-quality images; 3. Liver lesions were not observed with AP and PVP phases.

Design outcomes

Primary

MeasureTime frame
Area under the curve;Recall ;Precision;specificity;sensitivity;

Countries

China

Contacts

Public ContactYi Wei

Department of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

drweiyi057@163.com+86 181 0800 9568

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026